Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Catridecacog→

Catridecacog Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
606138-08-3
Molecular formula
Not available
Molecular weight
Not available
Drug class
Recombinant human coagulation factor XIII A-subunit (rFXIII-A2)haemostatic biologic
Mechanism of action
Replaces the deficient factor XIII A-subunit. Factor XIII is activated by thrombin and calcium and cross-links fibrin, stabilising the fibrin clot and supporting resistance to fibrinolysis.
Indications / reported uses
  • Long-term prophylaxis of bleeding in adults and paediatric patients aged 6 years and older with congenital factor XIII A-subunit deficiency
  • Treatment of breakthrough bleeding episodes and selected perioperative bleeding prevention in patients receiving prophylaxis, according to product-specific instructions

Sources: EMA EPAR — NovoThirteen · UK SmPC — NovoThirteen · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Catridecacog Environmental Risk Assessment (ERA) (the Catridecacog ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.